Tandem Diabetes Stock Price, News & Analysis

Tandem Diabetes Care (NASDAQ: TNDM) will announce its fourth quarter and full year 2021 results on February 22, 2022, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss the financial and operational highlights. Interested parties can join the call at (855) 427-4396 (toll-free) or (484) 756-4261 (international). An archived version of the webcast will be available for 30 days on their Investor Center website.

Tandem Diabetes Care announced key management appointments to enhance its leadership team for future growth. Rick Carpenter joins as Chief Technical Officer, bringing over 30 years of engineering experience. Libba Sapitsky becomes Senior Vice President of Customer Care, with extensive background in customer service operations. Rizwan Pervez is appointed Senior Vice President for Quality and Regulatory, having over 20 years in compliance leadership. These roles aim to support product expansion and pipeline execution as Tandem continues its mission to improve diabetes care.

Tandem Diabetes Care (NASDAQ: TNDM) will participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference on December 2, 2021. A pre-recorded fireside chat featuring CEO John Sheridan and CFO Leigh Vosseller will be available starting November 22, 2021, at 10:00 AM ET. Investors can access the chat on the Tandem Diabetes Investor Center website under 'Events & Presentations.'

Tandem Diabetes is committed to enhancing diabetes management through innovative solutions, highlighted by its flagship t:slim X2™ insulin pump.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) reported strong Q3 2021 results, with pump shipments up 43% and sales increasing 45% to $179.6 million. Gross profit rose 48% to $96.7 million, while net income shifted to $5.8 million from a loss in 2020. The company raised its 2021 sales guidance to $685-$695 million, reflecting a growth of 37-39%. International sales soared by 189%, and gross margin improved to 54%. Cash reserves reached $595 million, indicating robust liquidity.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced management will present company updates at two upcoming virtual investor conferences. The first is on November 9, 2021, at 12:10 PM ET during the Credit Suisse 30th Annual Virtual Healthcare Conference, followed by the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 4:00 PM ET. Both presentations will be webcast live, with recordings available for 30 days afterward. Interested parties can access the live and archive webcasts on Tandem's Investor Center website.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will release its third quarter 2021 results on November 3, 2021, after market close. A conference call is scheduled for 4:30 PM ET to discuss the financial and operational outcomes. Interested parties can access the call via toll-free and international dial-in numbers or through a webcast link provided in the release. The event will be archived for 30 days on Tandem's Investor Center website.

Tandem Diabetes Care (NASDAQ: TNDM) has announced upcoming presentations at several virtual investor conferences. These include:

• Wells Fargo 2021 Virtual Health Care Conference on September 9, 2021, at 4:35 PM ET
• Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 3:30 PM ET
• Baird 2021 Global Healthcare Conference on September 15, 2021, at 12:50 PM ET
• Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 4:35 PM ET

Live webcasts will be available, with recordings accessible for 30 days on the company’s investor website.

Tandem Diabetes Care (NASDAQ: TNDM) reported strong financial results for Q2 2021, with worldwide pump shipments up 81% to 33,817 units and sales rising 58% to $172.1 million. The gross margin increased to 54%, while operating income turned positive at $5.4 million. The company added 40% domestic pump shipments and 233% international growth, pushing adjusted EBITDA to $23.8 million. Cash reserves reached $545.3 million. Revised guidance for 2021 estimates sales between $670 million and $685 million, reflecting a growth of 34-37% year-over-year.

Tandem Diabetes Care (NASDAQ: TNDM) will present a company update at the UBS Genomics 2.0 and Medtech Innovations Summit on August 12, 2021, at 2:00 PM ET. The presentation will be available via a live webcast, with an archived recording accessible for 30 days thereafter. The link can be found on the Investor Center section of Tandem's website. Tandem focuses on improving the lives of people with diabetes through innovative medical devices, including their flagship product, the t:slim X2 insulin pump, which supports remote software updates and features integrated glucose monitoring.